A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085)

被引：0
|
作者：
Yu, E.
Massard, C.
Gross, M.
Wilding, G.
Posadas, E.
Culine, S.
Carducci, M. A.
Trudel, G.
Paliwal, P.
Sternberg, C.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Inst Gustave Roussy, Villejuif, France
[3] Louis Warschaw Prostate Canc Ctr, Los Angeles, CA USA
[4] UWCCC, Madison, WI USA
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] CHU Henri Mondor, F-94010 Creteil, France
[7] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] San Camillo Forlanini Hosp, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5147
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer
    Hussain, A.
    DiPaola, R. S.
    Baron, A. D.
    Higano, C. S.
    Tchekmedyian, N. S.
    Johri, A. R.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 492 - 497
  • [42] Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer
    Miller, K.
    Moul, J. W.
    Gleave, M.
    Fizazi, K.
    Nelson, J. B.
    Morris, T.
    Nathan, F. E.
    McIntosh, S.
    Pemberton, K.
    Higano, C. S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (02) : 187 - 192
  • [43] Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer
    K Miller
    J W Moul
    M Gleave
    K Fizazi
    J B Nelson
    T Morris
    F E Nathan
    S McIntosh
    K Pemberton
    C S Higano
    Prostate Cancer and Prostatic Diseases, 2013, 16 : 187 - 192
  • [44] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Hideyuki Akaza
    Hirotsugu Uemura
    Taiji Tsukamoto
    Seiichiro Ozono
    Osamu Ogawa
    Hideki Sakai
    Mototsugu Oya
    Mikio Namiki
    Satoshi Fukasawa
    Akito Yamaguchi
    Hiroji Uemura
    Yasuo Ohashi
    Hideki Maeda
    Atsushi Saito
    Kentaro Takeda
    Seiji Naito
    International Journal of Clinical Oncology, 2016, 21 : 773 - 782
  • [45] Efficacy of S-1 in Patients with Castration-Resistant Prostate Cancer: A Phase II Study
    Akaza, Hideyuki
    Ikemoto, Isao
    Namiki, Mikio
    Usami, Michiyuki
    Kobayashi, Mikio
    Fujimoto, Hiroyuki
    Tsukamoto, Taiji
    Naito, Seiji
    ONCOLOGY, 2010, 78 (5-6) : 323 - 328
  • [46] A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
    Chi, K. N.
    Ellard, S. L.
    Hotte, S. J.
    Czaykowski, P.
    Moore, M.
    Ruether, J. D.
    Schell, A. J.
    Taylor, S.
    Hansen, C.
    Gauthier, I.
    Walsh, W.
    Seymour, L.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 746 - 751
  • [47] A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
    Akaza, Hideyuki
    Uemura, Hirotsugu
    Tsukamoto, Taiji
    Ozono, Seiichiro
    Ogawa, Osamu
    Sakai, Hideki
    Oya, Mototsugu
    Namiki, Mikio
    Fukasawa, Satoshi
    Yamaguchi, Akito
    Uemura, Hiroji
    Ohashi, Yasuo
    Maeda, Hideki
    Saito, Atsushi
    Takeda, Kentaro
    Naito, Seiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (04) : 773 - 782
  • [48] Effect of fulvestrant on PSA doubling time in patients with castration-resistant prostate cancer (CRPC)
    Srinivas, S.
    Harshman, L. C.
    Feldman, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Castration-Resistant Prostate Cancer (CRPC): understanding the mechanisms and implications for management
    Bessede, T.
    Malavaud, B.
    Staerman, F.
    Culine, S.
    PROGRES EN UROLOGIE, 2013, 23 : 6 - 11
  • [50] DaroACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC).
    Beer, Tomasz M.
    Shore, Neal D.
    Morgans, Alicia K.
    Winters-Stone, Kerri M.
    Wefel, Jeffrey Scott
    Ortiz, Jorge A.
    Reeves, John A.
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345